Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M138Revenue $M46.2Net Margin (%)1.8Altman Z-Score11.4
Enterprise Value $M41.9EPS $0.1Operating Margin %4.2Piotroski F-Score6
P/E(ttm)180Beneish M-Score3.1Pre-tax Margin (%)0.6Higher ROA y-yN
Price/Book1.210-y EBITDA Growth Rate %--Quick Ratio10.6Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %--Current Ratio12.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %1,154ROA % (ttm)0.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)0.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.5ROIC % (ttm)8.1Gross Margin Increase y-yY

Gurus Latest Trades with GENC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
GENCJohn Keeley 2010-03-31 Sold Out $6.9 - $7.8
$ 14.4397%Sold Out0
GENCJohn Keeley 2009-09-30 Buy $6.38 - $8.35
$ 14.43100%New holding30,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GENC is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

GENC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Air DavidDirector 2016-03-03Sell5,000$13.46.42view
Houtkin Sherry10% Owner 2016-03-02Sell10,000$13.386.58view
Houtkin Sherry10% Owner 2016-03-01Sell20,000$13.545.32view
Houtkin Sherry10% Owner 2016-02-26Sell50,000$13.118.77view
ELLIOTT MARC Gpresident 2016-02-17Sell9,140$12.6812.46view
ELLIOTT MARC GPresident 2015-12-15Sell19,044$12.7411.93view
Houtkin Sherry10% Owner 2015-10-06Sell80,000$9.2654view
Houtkin Sherry10% Owner 2015-05-06Sell70,000$9.255view
LYONS JEANNE MSecretary 2015-03-16Sell985$9.7845.81view
LYONS JEANNE MSecretary 2015-03-16Sell985$9.7845.81view

Quarterly/Annual Reports about GENC:

News about GENC:

Articles On GuruFocus.com
Mario Gabelli Gives Stock Recommendations Feb 26 2016 
Winning with the Net Current Asset Value Approach to Stocks Sep 04 2013 
Ben Graham Net-Net Newsletter: TSR (TSRI) One Year Later Apr 09 2012 
“Assign Yourself the Right Story” Mar 05 2012 
Ben Graham Net-Net Newsletter: Gencor (GENC) One Year Later Feb 29 2012 
How Long Should You Hold a Net-Net? Feb 13 2012 
Opt-Sciences $OPST- Follow Up Feb 01 2012 
Four Stocks to Fit in a Basket of Negative Enterprise Value with Certain Profitability Dec 23 2011 
Gencor ($GENC)- A free business with a huge portfolio Dec 22 2011 
Genco Industries: $15 Million in Cash and the Company for Free Sep 28 2011 

More From Other Websites
Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting Apr 20 2016
Genmab Updates Financial Guidance for 2016 Apr 20 2016
ETF’s with exposure to Gencor Industries, Inc. : April 8, 2016 Apr 08 2016
Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 07 2016
Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding... Apr 04 2016
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed and Refractory... Apr 01 2016
Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or... Mar 30 2016
Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and... Mar 21 2016
GENCOR INDUSTRIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 10 2016
GENCOR INDUSTRIES INC Financials Feb 13 2016
Gencor posts 1Q profit Feb 10 2016
Gencor posts 1Q profit Feb 10 2016
Gencor Releases First Quarter Fiscal 2016 Results Feb 10 2016
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 10 2016
GENCOR INDUSTRIES INC Files SEC form 10-Q, Quarterly Report Feb 10 2016
Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or... Jan 19 2016
Daratumumab Data Published in The Lancet Shows Encouraging Efficacy in Heavily Pretreated and... Jan 07 2016
Genmab Achieves $3 Million Milestone in DuoBody Platform Collaboration with Janssen Dec 21 2015
Genmab Announces Completion of Agreement to Transfer Remaining Ofatumumab Rights Dec 21 2015
Genmab Achieves $3 Million Milestone for Progress in DuoBody Platform Collaboration with Janssen Dec 18 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)